Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Choisir judicieusement les médicaments anticancéreux: Disponibilité, accessibilité et abordabilité en Afrique

Choosing Wisely Senegal 2022

Published: 6 Feb 2023

Views: 41

Rating:

Save

Prof Moctar Toure - University Hospital Medical Center at Treichville, Abidjan, Côte d'Ivoire

Le Pr Touré intervient au congrès ecancer "Choosing Wisely Senegal 2022", qui s'est tenu à Dakar le 16 décembre 2022. Il s'agissait d'un congrès conjoint avec la Société sénégalaise de lutte contre le cancer (SOSECAN) et l'Association sénégalaise de soins palliatifs (ASSOPA).

Le professeur Touré discute du choix judicieux des médicaments anticancéreux : disponibilité, accessibilité et prix abordable en Afrique.

Related Videos

Innovating cancer care access for low and middle-income countries

Lacy Hubbard - Founding President and CEO, Elekta Foundation

Innovating cancer care access for low and middle-income countries ( Lacy Hubbard - Founding President and CEO, Elekta Foundation )

Addressing cancer control challenges in Africa

Dr Zainab Bagudu - MedicAid Cancer Foundation, Abuja, Nigeria

Addressing cancer control challenges in Africa ( Dr Zainab Bagudu - MedicAid Cancer Foundation, Abuja, Nigeria )

Prostate cancer

Dr Alison Tree - Institute of Cancer Research, London, UK

Prostate cancer ( Dr Alison Tree - Institute of Cancer Research, London, UK )

Rectal cancer

Dr Rebecca Wong - Princess Margaret Cancer Center, Toronto, Canada

Rectal cancer ( Dr Rebecca Wong - Princess Margaret Cancer Center, Toronto, Canada )

Synthetic biology and precision medicine in blood and gynaecological cancers

Dr Mutsa Takundwa - Council for Scientific and Industrial Research, Pretoria, South Africa

Synthetic biology and precision medicine in blood and gynaecological cancers ( Dr Mutsa Takundwa - Council for Scientific and Industrial Research, Pretoria, South Africa )

KEYNOTE-756 trial shows increased response in ER+/HER2- breast cancer

Dr Fatima Cardoso - Champalimaud Cancer Center, Lisbon, Portugal

KEYNOTE-756 trial shows increased response in ER+/HER2- breast cancer ( Dr Fatima Cardoso - Champalimaud Cancer Center, Lisbon, Portugal )

Feasibility and safety of boost at 74 Gy based on interim FDG-PET during thoracic radio-chemotherapy for NSCLC patients

Prof Gerard Zalcman - Université de Paris, Paris, France

Feasibility and safety of boost at 74 Gy based on interim FDG-PET during thoracic radio-chemotherapy for NSCLC patients ( Prof Gerard Zalcman - Université de Paris, Paris, France )

Adjuvant radiotherapy has no benefit following radical prostatectomy

Prof Noel Clarke - The Christie NHS Foundation Trust, Manchester, UK

Adjuvant radiotherapy has no benefit following radical prostatectomy ( Prof Noel Clarke - The Christie NHS Foundation Trust, Manchester, UK )

Adagrasib shows durable clinical benefit in advanced KRAS-mutant NSCLC

Dr Shirish Gadgeel - Henry Ford Cancer Institute, Detroit, USA

Adagrasib shows durable clinical benefit in advanced KRAS-mutant NSCLC ( Dr Shirish Gadgeel - Henry Ford Cancer Institute, Detroit, USA )

More from ecancer